Forum Agenda
-
Medicine-Engineering Integration and Innovative Medical Devices
-
China’s Innovation Ecosystem and Models
-
Research Translation and Early-stage Project Incubation Meeting
-
Accelerating Innovation Through External Collaboration Meeting
-
Leveraging China's Innovation to Accelerate Global Drug R&D Meeting
-
USTC Original Innovation Power: Alumni Enterprise Innovation Matrix Meeting
-
Clinical Translation of Medical Research Achievements Meeting
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
JunHe LLP Session:New Models of Cross-Border Pharmaceutical Cooperation Session
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
The Booming Radiopharmaceuticals Session
Stay tuned
Opening Remarks
Yumin Zhang: Founder, Anchoray Inc.; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)
Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry, and International Association of Advanced Materials
Case Analysis of Preclinical Evaluation for Radiopharmaceuticals
Conglin Zuo: Founder, Hexin Pharmaceutical ; Vice Chairman, JOINN Laboratories; Member of the Drug Toxicology Committee, Chinese Pharmacological Society;Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association
Clinical Development Strategies for Radiotherapeutic Drugs in Oncology
Yan Gong: General Manager, Honghong Pharma
Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu(Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li: Partner, Stars Capital
Chunguang Liu: Managing Partner, Tailong VC
Feng Yu: Founder & CEO, ELI Radiopharma
Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals
Xiangsheng Ye: CSO, AlphaGen Therapeutics
Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals?
Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub
More guests to be confirmed...